ClinicalTrials.gg
Active, not recruitingNCT06555796Updated Sep 4, 2026

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

A Phase 1 interventional study of Xaluritamig in Prostate Cancer, High-risk Biochemical Recurrence and High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, sponsored by Amgen. Active, not recruiting at 11 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Enrollment
13th of 21
50 · median 64
Started
2024
with 2 others
Phase 1
9 of 23
3 open now
Registered
18th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 1, and was the 18th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).

03

Conditions studied

  • Prostate Cancer
  • High-risk Biochemical Recurrence
  • High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
  • Non-metastatic Castration-sensitive Prostate Cancer

Browse trials for

Keywords

  • Xaluritamig
  • T-Cell Engager
  • AMG509
  • STEAP1
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate at initial , without neuroendocrine differentiation, signet cell, or small cell features.
  • Prostate cancer initially treated by radical prostatectomy (RP) or radiotherapy (XRT) (including brachytherapy) or both (eg, salvage radiotherapy), with curative intent.
  • PSA doubling time ≤ 12 months.
  • Participants must have biochemically recurrent disease after definitive treatment to prostate by either RP or XRT.
  • Screening PSA by the local laboratory ≥ 0.2 ng/mL for participants who had RP (with or without XRT) as primary treatment for prostate cancer or at least 2 ng/mL above the nadir (local assessments) for participants who had XRT or brachytherapy only as primary treatment for prostate cancer.
  • Serum testosterone ≥ 150 ng/dL (5.2 nmol/L).
  • Participants must have undergone a prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan during or within 3 months of screening.

Exclusion criteria

Exclusion Criteria

  • Present evidence of disease in conventional CT scan and/or bone scan
  • Participants that present PSMA-positive lesions in the PSMA PET scan may be enrolled if the conventional imaging does not show suspicion of metastatic disease.
  • Prior hormonal therapy, exceptions include:

    • /adjuvant therapy to treat prostate cancer ≤ 36 months in duration and ≥ 9 months before enrollment, or
    • A single dose or a short course (≤ 6 months) of hormonal therapy given for rising PSA ≥ 9 months before enrollment.
  • Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, enzalutamide, apalutamide, or darolutamide for prostate cancer.
  • Abiraterone acetate, enzalutamide, apalutamide, or darolutamide are allowed if administered in a neoadjuvant/adjuvant setting ≤ 36 months in duration and ≥ 9 months before enrollment.
  • Prior systemic biologic therapy, including immunotherapy, for prostate cancer.
  • If, in the investigator's opinion, salvage therapy is the preferred intervention.
  • disease requiring systemic within the past 2 years.
  • Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.
  • Requirement for chronic systemic therapy (prednisone dose > 10 mg/day or equivalent) or any other immunosuppressive therapies (including anti tumor necrosis factor alpha [TNFα] therapies) unless stopped (with adequate tapering) within 7 days prior to dosing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Xaluritamig

    Xaluritamig will be administered as a short-term intravenous (IV) infusion for a total of 6 cycles. One treatment cycle consists of 28 days for cycles 1-2 and 56 days for cycles 3-6.

    Drug: Xaluritamig

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Events categorized as adverse events (AEs) starting on or after first dose of investigational product (xaluritamig) as determined by the flag indicating if the AE started prior to the first dose on the Events Electronic Case Report Form (eCRF) and including 30 days after the last dose of investigational product (xaluritamig) or end of study date, whichever is earlier.

    Time frame: Up to approximately 2 years

  2. Number of Participants Experiencing Treatment-related Adverse Events (TRAEs)

    A TRAE is any TEAE that per investigators' review has a reasonable possibility of being caused by the investigational product (xaluritamig) determined by the flag indicating an event may have been caused by the investigational product (xaluritamig) on the Events eCRF. In the unlikely event that the flag is missing, the TEAE will be considered related.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Time to Prostate-specific Antigen (PSA) Progression

    Time frame: Up to 50 months

  2. Number of Participants With a PSA 50 Response

    Time frame: Up to approximately 50 months

  3. Number of Participants With a PSA 90 Response

    Time frame: Up to approximately 50 months

  4. Duration of PSA 50 Response

    Time frame: Up to approximately 50 months

  5. Duration of PSA 90 Response

    Time frame: Up to approximately 50 months

  6. Number of Participants With Undetectable PSA

    Time frame: Up to approximately 50 months

  7. Time to Initiation of Androgen Deprivation Therapy or Androgen Receptor Directed Therapy

    Time frame: Up to approximately 50 months

  8. Time to First use of new Anticancer Therapy

    Time frame: Up to approximately 50 months

  9. Time to Metastatic Disease/Progression

    Time frame: Up to approximately 50 months

  10. Metastasis-free Survival (MFS)

    Time frame: Up to approximately 50 months

  11. Number of Participants Completing Xaluritamig Monotherapy Treatment

    Time frame: Up to approximately 24 months

  12. Maximum Serum Concentration (Cmax) of Xaluritamig

    Time frame: Up to approximately 24 months

  13. Time to Cmax (Tmax) of Xaluritamig

    Time frame: Up to approximately 24 months

  14. Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of Xaluritamig

    Time frame: Up to approximately 24 months

  15. Terminal Half-life (t1/2) of Xaluritamig

    Time frame: Up to approximately 24 months

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 29 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 15, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Mar 13, 2027
CompletionEst.
May 7, 2029
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06555796
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Sep 23, 2024
Primary completion
Mar 13, 2027 (estimated)
Completion
May 7, 2029 (estimated)
Last update
Sep 4, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xaluritamig

Start the discussion